	Application No.	Applicant(s)	
Notice of Allowability	10/775,699	BEBBINGTON ET A	L.
	Examiner	Art Unit	
	Tamthom N. Truong	1624	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
1. X This communication is responsive to <u>amendment of 4-20-07</u> .			
2. The allowed claim(s) is/are <u>1 and 8-16</u> .			
<ul> <li>3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some* c) None of the:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> <li>Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.</li> </ul>			
<ul> <li>THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.</li> <li>A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.</li> </ul>			
<ul> <li>5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.</li> <li>(a) including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached</li> <li>1) hereto or 2) to Paper No./Mail Date</li> <li>(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date</li> <li>Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).</li> </ul>			
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.			
<ul> <li>Attachment(s)</li> <li>1. ☑ Notice of References Cited (PTO-892)</li> <li>2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)</li> <li>3. ☑ Information Disclosure Statements (PTO/SB/08),</li></ul>		(PTO-413), te ment/Comment	MINER
U.S. Patent and Trademark Office PTOL-37 (Rev. 08-06)  Notice of Allowability  Part of Paper No./Mail Date 20070717			

## **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

In the preliminary amendment of 1-10-04:

The section of Cross-Reference To Related Applications, line 3, after the year '2001,' insert – now U.S. Patent No. 6,727,251, --.

In the current amendment:

Claim 1: line 10, in the definition of Q, delete "-CH(R)-" (i.e., the last group), and insert -- - $CH(R^6)$  – in its place.

The amendment was necessary because the superscript on the R group is blurry. The appropriate R<sup>6</sup> group is found in the Pregrant Publication US 2004/0167141 A1.

## Allowable Subject Matter

Applicants' response of 4-20-07 has overcome all 112 rejections of previous action by limiting the core of formula II to pyrimidine and quinazoline.

With no other outstanding rejection, claims 1, 8-16 are allowed.

## Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

The invention is drawn to compounds of substituted 2-pyrazolylamino-pyrimidine or 2-pyrazolylamino-quinazoline, and pharmaceutical composition thereof. The closest reference, **Pease et. al.** (US 6,838,464 B2), generically teaches a pyrimdinyl compound with substituents at the 2- and 4-positions corresponding to those of the instant formula II. However, said compound lacks a substituent at the 6-position corresponding to the instant R<sup>y</sup>. Thus, there is no equivalency teaching for motivation to make a case of prima facie obviousness.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 571-272-0676. The examiner can normally be reached on M, T and Th (9:00-5:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1624

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Tamthom N. Truong

Examiner Art Unit 1624

7-17-07

JAMES O. WILSON SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600